Subscribe
Subscribe

HERAN Partners Raises €90 Million Fund for European Healthtech

Belgian venture capital firm HERAN Partners has announced a €90 million close for its second healthtech-focused fund, HERAN HealthTech Fund II, and says it aims to scale to €110–120 million. The firm invests in early-stage medtech and healthtech companies across Europe, backing technologies designed to make healthcare and life sciences R&D more efficient, data-driven, and scalable.

Belgian Biotech Agomab Debuts on Nasdaq with a $200 Million IPO

Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.

Hospitals and Belgian Companies Unite to Shape the Future of Healthcare

On 29 January 2026, 400 Belgian healthcare stakeholders — hospital executives, policymakers, and innovators — gathered in Brussels to help shape the future of healthcare. The objective was to connect hospital needs with the innovative technologies developed by Belgian companies. Two projects were honored during the event’s Innovation Awards: Baby Detect and SIM BLOOD.

European Biotech Act: New initiative to mobilize €10 billion investment for Europe’s biotech sector

The European Commission and the European Investment Bank (EIB) Group have announced an initiative to mobilize €10 billion in investment in 2026-27 into the biotech and life sciences sector. The project aims to give a significant boost to the EU's competitiveness in biotechnology, by addressing the EU's current investment gap and mobilizing public-private investment into promising new health solutions.

Celebrating the Pitch Winners of HealthTech Investor Summit 2025

Europe’s healthtech pipeline was on full display at the HealthTech Investor Summit 2025 in Utrecht, with the regions brightest rising stars in the spotlight. From surgical robotics and implantable devices to bioelectronics and next-generation diagnostics, here are the pitching companies that stood out to both the judges and audience.

Trio of scientists win Nobel Prize for immune system regulation

Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi have been awarded the Nobel Prize in Physiology or Medicine 2025 for their groundbreaking discoveries in peripheral immune tolerance—how the immune system uses regulatory T cells to prevent other immune cells from attacking our own body. Their work laid the foundation for a new field of research and spurred the development of treatments for cancer and autoimmune diseases.

Fund+ portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk in potential 1-billion-euro deal

Novo Nordisk will acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in RNA-based therapies that have the potential to prevent, repair and reverse diseases of the heart. The company’s approach targets distinctive non-coding RNAs to address the root causes of cardiac dysfunctions and achieve lasting patient impact.

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Azalea Vision Secures Prestigious European Innovation Council (EIC) Transition Grant

Innovative Smart Contact Lens Developer Awarded €2.5M in Funding for Groundbreaking Ocular Health Technology